Tiber Creek Partners, LLC provides detailed business analysis, strategic planning, and substantive content, including scientific input, to biotechnology companies that seek to use non-dilutive capital from the U.S. Government, foreign governments, and non-governmental organizations as part of their commercialization objectives. We offer a full understanding of funding and procurement opportunities and provide the strategy and materials necessary communicate the advantages and the state of development of our clients’ technology so that it resonates most effectively with funding and purchasing decision-makers.
Tiber Creek Partners is a multi-faceted resource for businesses interested in a range of biotechnology applications, including emerging infectious diseases, biodefense and bioterrorism, pandemic influenza preparedness, military medicine, regenerative medicine, neglected and tropical diseases, patient-centered and personalized medicine.
We support our clients meet their business objectives by preparing and executing funding strategies for technological advancements in life sciences that create profitable partnerships between the pharmaceutical and biotechnology industries with the financial community, private investors, governments, and non-governmental organizations.
Our team employs a range of tools to successfully create markets for biotechnology opportunities of interest to federal government purchasers such as the Department of Health and Human Services (HHS) and its agencies including the Biomedical Advanced Research and Development Authority (BARDA), National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC); the Department of Defense (DoD) and its agencies; the European Union (EU) and various defense and health ministries throughout Europe, as well as non-governmental funding enterprises around the globe. These tools include providing broad-ranging reports that analyze funding streams to match them against the business goals of our clients, as well as meaningful content to our client’s scientific materials.